Silverback Therapeutics racks up $47.5 mln
Seattle-based Silverback Therapeutics Inc, a biotech company developing a pipeline of "systemically delivered, locally active" therapies, has extended its Series A financing round, bringing in the total tally to $47.5 million. OrbiMed led the round with participation from return backers Celgene Corporation and Alexandria Venture Investments.
21 September 2018•1 min read
